{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:55Z","timestamp":1740147775226,"version":"3.37.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32DK07780"],"award-info":[{"award-number":["T32DK07780"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11899-023-00710-x","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T03:24:12Z","timestamp":1692933852000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Central Nervous System Relapse in T and NK cell Lymphomas"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-2176","authenticated-orcid":false,"given":"Eleanor P.","family":"Taranto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-7393","authenticated-orcid":false,"given":"Rahul S.","family":"Bhansali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"710_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353. https:\/\/doi.org\/10.1182\/blood.2022015851.","journal-title":"Blood"},{"key":"710_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo B, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"key":"710_CR3","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. Project IT-CL. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"key":"710_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective. Int T-Cell Project Haematol. 2018;103:1191\u20137. https:\/\/doi.org\/10.3324\/haematol.2017.186577.","journal-title":"Int T-Cell Project Haematol"},{"key":"710_CR5","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/annonc\/mdq645","volume":"22","author":"JH Yi","year":"2011","unstructured":"Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22:1636\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdq645.","journal-title":"Ann Oncol"},{"key":"710_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2014-12-616961","volume":"126","author":"F Ellin","year":"2015","unstructured":"\u2022\u2022 Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126:36\u201341. https:\/\/doi.org\/10.1182\/blood-2014-12-616961. Largest published dataset on CNS relapse in PTCL with risk factor analysis.","journal-title":"Blood"},{"key":"710_CR7","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1182\/blood-2010-02-266890","volume":"115","author":"B Pro","year":"2010","unstructured":"Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115:5427. https:\/\/doi.org\/10.1182\/blood-2010-02-266890.","journal-title":"Blood"},{"key":"710_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/0284186X.2015.1118656","volume":"55","author":"R Gurion","year":"2016","unstructured":"Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, et al. Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol. 2016;55:561\u20136. https:\/\/doi.org\/10.3109\/0284186X.2015.1118656.","journal-title":"Acta Oncol"},{"key":"710_CR9","doi-asserted-by":"publisher","first-page":"e0191461","DOI":"10.1371\/journal.pone.0191461","volume":"13","author":"D Chihara","year":"2018","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018;13:e0191461. https:\/\/doi.org\/10.1371\/journal.pone.0191461.","journal-title":"PLoS One"},{"key":"710_CR10","doi-asserted-by":"publisher","first-page":"874462","DOI":"10.3389\/fonc.2022.874462","volume":"12","author":"H Mocikova","year":"2022","unstructured":"Mocikova H, Pytl\u00edk R, Benesova K, Janikova A, Duras J, Sykorova A, et al. Peripheral T-cell lymphomas involving the central nervous system: a report from the Czech Lymphoma Study Group Registry. Front Oncol. 2022;12:874462. https:\/\/doi.org\/10.3389\/fonc.2022.874462.","journal-title":"Front Oncol"},{"key":"710_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1023\/a:1008418727472","volume":"9","author":"A L\u00f3pez-Guillermo","year":"1998","unstructured":"L\u00f3pez-Guillermo A, Cid J, Salar A, L\u00f3pez A, Montalb\u00e1n C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L Classification. Ann Oncol. 1998;9:849\u201355. https:\/\/doi.org\/10.1023\/a:1008418727472.","journal-title":"Ann Oncol"},{"key":"710_CR12","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970\u20136. https:\/\/doi.org\/10.1200\/JCO.2012.44.7524.","journal-title":"J Clin Oncol"},{"key":"710_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1023\/a:1008394827806","volume":"11","author":"C Haioun","year":"2000","unstructured":"Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin\u2019s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol. 2000;11:685\u201390. https:\/\/doi.org\/10.1023\/a:1008394827806.","journal-title":"Ann Oncol"},{"key":"710_CR14","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","volume":"102","author":"H Tilly","year":"2003","unstructured":"Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284\u20139. https:\/\/doi.org\/10.1182\/blood-2003-02-0542.","journal-title":"Blood"},{"key":"710_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis ofnon-Hodgkin\u2019s lymphoma: a risk model. Ann Oncol. 2002;13:1099\u2013107. https:\/\/doi.org\/10.1093\/annonc\/mdf175.","journal-title":"Ann Oncol"},{"key":"710_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","volume":"91","author":"K van Besien","year":"1998","unstructured":"van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178\u201384. https:\/\/doi.org\/10.1182\/blood.V91.4.1178.","journal-title":"Blood"},{"key":"710_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2013a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdl327.","journal-title":"Ann Oncol"},{"key":"710_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516 \u2013 the Southwest Oncology Group. J Clin Oncol. 2009;27:114\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.16.8021.","journal-title":"J Clin Oncol"},{"key":"710_CR19","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.65.6520.","journal-title":"J Clin Oncol"},{"key":"710_CR20","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2021-148868","volume":"138","author":"RS Bhansali","year":"2021","unstructured":"Bhansali RS, Ganesan N, Stuver RN, Horwitz SM, Wudhikarn K, Hwang SR, et al. A multi-institutional retrospective analysis of T-cell lymphomas with central nervous system relapse. Blood. 2021;138:1382\u20131382. https:\/\/doi.org\/10.1182\/blood-2021-148868.","journal-title":"Blood"},{"key":"710_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. https:\/\/doi.org\/10.3389\/fmicb.2012.00388.","journal-title":"Front Microbiol"},{"key":"710_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/1097-0142(19900115)65:2<327::aid-cncr2820650224>3.0.co;2-w","volume":"65","author":"T Teshima","year":"1990","unstructured":"Teshima T, Akashi K, Shibuya T, Taniguchi S, Okamura T, Harada M, et al. Central nervous system involvement in adult T-cell leukemia\/lymphoma. Cancer. 1990;65:327\u201332. https:\/\/doi.org\/10.1002\/1097-0142(19900115)65:2%3c327::aid-cncr2820650224%3e3.0.co;2-w.","journal-title":"Cancer"},{"key":"710_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1182\/blood-2021-151447","volume":"138","author":"R Patel","year":"2021","unstructured":"Patel R, Rahman S, Shah N, Thakkar A, et al. Predictors of central nervous system (CNS) involvement in North American adult T-cell leukemia lymphoma (ATLL) and their survival pattern. Blood. 2021;138:1400. https:\/\/doi.org\/10.1182\/blood-2021-151447.","journal-title":"Blood"},{"key":"710_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/annonc\/mdp412","volume":"21","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. When do we need central nervous system prophylaxis in patients with extranodal NK\/T-cell lymphoma, nasal type? Ann Oncol. 2010;21:1058\u201363. https:\/\/doi.org\/10.1093\/annonc\/mdp412.","journal-title":"Ann Oncol"},{"key":"710_CR25","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/blood.2020005026","volume":"136","author":"H Kim","year":"2020","unstructured":"\u2022\u2022 Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, et al. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer\/T-cell lymphoma. Blood. 2020;136:2548\u201356. https:\/\/doi.org\/10.1182\/blood.2020005026. A risk score developed for CNS relapse in patients with ENKTL that was validated in an external cohort.","journal-title":"Blood"},{"key":"710_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1182\/blood-2022-160090","volume":"140","author":"RS Bhansali","year":"2022","unstructured":"\u2022\u2022 Bhansali RS, Ellin F, Cao M, Relander T, Li W, Long Q, et al. CNS relapse in T-cell lymphoma index: a risk score to predict central nervous system relapse in patients with T-cell lymphomas. Blood. 2022;140:1481\u20134. https:\/\/doi.org\/10.1182\/blood-2022-160090. Preliminary data presented at the American Society of Hematology meeting for a new risk score to predict CNS relapse in patients with PTCL.","journal-title":"Blood"},{"key":"710_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.2021012888","volume":"139","author":"VM Orellana-Noia","year":"2022","unstructured":"\u2022 Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139:413\u201323. https:\/\/doi.org\/10.1182\/blood.2021012888. Large retrospective study demonstrating no benefit to CNS prophylaxis for high-risk B-cell NHL.","journal-title":"Blood"},{"key":"710_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:285\u2013308. https:\/\/doi.org\/10.6004\/jnccn.2022.0015.","journal-title":"J Natl Compr Canc Netw"},{"key":"710_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1200\/JCO.18.00501","volume":"37","author":"LB Cook","year":"2019","unstructured":"\u2022 Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677\u201387. https:\/\/doi.org\/10.1200\/JCO.18.00501. Updated recommendations for diagnosis and treatment of ATLL, along with discussion about CNS screening and prophylactic therapy.","journal-title":"J Clin Oncol"},{"key":"710_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02983215","volume":"77","author":"K Tsukasaki","year":"2003","unstructured":"Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164\u201370. https:\/\/doi.org\/10.1007\/BF02983215.","journal-title":"Int J Hematol"},{"key":"710_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375\u201382. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02737.x.","journal-title":"Br J Haematol"},{"key":"710_CR32","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364. https:\/\/doi.org\/10.1200\/JCO.2007.11.9958.","journal-title":"J Clin Oncol"},{"key":"710_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","volume":"104","author":"MW Pitz","year":"2011","unstructured":"Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol. 2011;104:629\u201338. https:\/\/doi.org\/10.1007\/s11060-011-0564-y.","journal-title":"J Neurooncol"},{"key":"710_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood.2019004045","volume":"137","author":"LB Cook","year":"2021","unstructured":"Cook LB, Phillips AA. How I treat adult T-cell leukemia\/lymphoma. Blood. 2021;137:459\u201370. https:\/\/doi.org\/10.1182\/blood.2019004045.","journal-title":"Blood"},{"key":"710_CR35","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095\u2013100. https:\/\/doi.org\/10.1182\/blood-2013-12-542142.","journal-title":"Blood"},{"key":"710_CR36","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709\u201317. https:\/\/doi.org\/10.1182\/blood-2017-05-780049.","journal-title":"Blood"},{"key":"710_CR37","doi-asserted-by":"publisher","first-page":"921657","DOI":"10.12659\/AJCR.921657","volume":"21","author":"H Mocikov\u00e1","year":"2020","unstructured":"Mocikov\u00e1 H, Malikova H, Holesta M, Elturki A, Campr V, Kozak T. Durable response to brentuximab vedotin-based chemotherapy in refractory Hodgkin lymphoma with central nervous system (CNS) involvement. Am J Case Rep. 2020;21:921657. https:\/\/doi.org\/10.12659\/AJCR.921657.","journal-title":"Am J Case Rep"},{"key":"710_CR38","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1080\/10428194.2016.1222375","volume":"58","author":"KL Chan","year":"2017","unstructured":"Chan KL, van der Weyden C, Khoo C, Lade S, Blombery P, Westerman D, et al. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2017;58:996\u20138. https:\/\/doi.org\/10.1080\/10428194.2016.1222375.","journal-title":"Leuk Lymphoma"},{"key":"710_CR39","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134:1395\u2013405. https:\/\/doi.org\/10.1182\/blood.2019001285.","journal-title":"Blood"},{"key":"710_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","volume":"131","author":"JE Amengual","year":"2018","unstructured":"Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131:397\u2013407. https:\/\/doi.org\/10.1182\/blood-2017-09-806737.","journal-title":"Blood"},{"key":"710_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7164\/antibiotics.47.315","volume":"47","author":"H Ueda","year":"1994","unstructured":"Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III Antitumor activities on experimental tumors in mice. J Antibiot. 1994;47:315\u201323. https:\/\/doi.org\/10.7164\/antibiotics.47.315.","journal-title":"J Antibiot"},{"key":"710_CR42","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","volume":"121","author":"E Toumishey","year":"2015","unstructured":"Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121:716\u201323. https:\/\/doi.org\/10.1002\/cncr.29103.","journal-title":"Cancer"},{"key":"710_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"\u2022 Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molu\u00e7on-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020. Ann Oncol. 2019;30:621\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz032. Phase II trial demonstrating CNS activity of lenalidomide in lymphoma.","journal-title":"Ann Oncol"},{"key":"710_CR44","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1200\/JCO.2011.34.7252","volume":"29","author":"JL Rubenstein","year":"2011","unstructured":"Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011;29:e595\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.34.7252.","journal-title":"J Clin Oncol"},{"key":"710_CR45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/ajh.22148","volume":"86","author":"MC Cox","year":"2011","unstructured":"Cox MC, Mannino G, Lionetto L, Naso V, Simmaco M, Spiriti MA. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system? Am J Hematol. 2011;86:957. https:\/\/doi.org\/10.1002\/ajh.22148.","journal-title":"Am J Hematol"},{"key":"710_CR46","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, et al. Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2:1595\u2013607. https:\/\/doi.org\/10.1182\/bloodadvances.2017014845.","journal-title":"Blood Adv"},{"key":"710_CR47","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0613.","journal-title":"Cancer Discov"},{"key":"710_CR48","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833-843.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.012.","journal-title":"Cancer Cell"},{"key":"710_CR49","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood-2014-12-617779","volume":"126","author":"H Richly","year":"2015","unstructured":"Richly H, Kim TM, Schuler M, Kim D-W, Harrison SJ, Shaw AT, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase\u2013rearranged anaplastic large-cell lymphoma. Blood. 2015;126:1257\u20138. https:\/\/doi.org\/10.1182\/blood-2014-12-617779.","journal-title":"Blood"},{"key":"710_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/10428194.2020.1839658","volume":"62","author":"M Chen","year":"2021","unstructured":"Chen M, Fu X, Huang H, Wang Z, Fang X, Yao Y-Y, et al. Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Leuk Lymphoma. 2021;62:571\u201380. https:\/\/doi.org\/10.1080\/10428194.2020.1839658.","journal-title":"Leuk Lymphoma"},{"key":"710_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4749452","volume":"2022","author":"J Verran","year":"2022","unstructured":"Verran J, Mathavan V. Alectinib monotherapy in isolated central nervous system relapse of ALK-positive anaplastic large cell lymphoma. Case Rep Hematol. 2022;2022:1\u20134. https:\/\/doi.org\/10.1155\/2022\/4749452.","journal-title":"Case Rep Hematol"},{"key":"710_CR52","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.clml.2019.03.001","volume":"19","author":"DR Reed","year":"2019","unstructured":"Reed DR, Hall RD, Gentzler RD, Volodin L, Douvas MG, Portell CA. Treatment of refractory ALK rearranged anaplastic large cell lymphoma with alectinib. Clin Lymphoma Myeloma Leuk. 2019;19:e247\u201350. https:\/\/doi.org\/10.1016\/j.clml.2019.03.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"710_CR53","doi-asserted-by":"publisher","first-page":"106164","DOI":"10.1016\/j.leukres.2019.05.014","volume":"83","author":"SB Tomlinson","year":"2019","unstructured":"Tomlinson SB, Sandwell S, Chuang ST, Johnson MD, Vates GE, Reagan PM. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib. Leuk Res. 2019;83:106164. https:\/\/doi.org\/10.1016\/j.leukres.2019.05.014.","journal-title":"Leuk Res"},{"key":"710_CR54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/cancers15030925","volume":"15","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Barta SK. Central nervous system progression\/relapse in mature T- and NK-cell lymphomas. Cancers. 2023;15:925. https:\/\/doi.org\/10.3390\/cancers15030925.","journal-title":"Cancers"},{"key":"710_CR55","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2021-144933","volume":"138","author":"JK Lue","year":"2021","unstructured":"Lue JK, Ma H, Marchi E, Spivack JH, O\u2019Connor OA. Peripheral T-cell lymphoma involvement of the central nervous system: impact of novel therapeutics on clinical outcomes. Blood. 2021;138:2469. https:\/\/doi.org\/10.1182\/blood-2021-144933.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00710-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:18:41Z","timestamp":1702030721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00710-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00710-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"16 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Eleanor P. Taranto reports personal fees from the Curbsiders Internal Medicine Podcast, outside the submitted work; Rahul S. Bhansali reports personal fees from Alva10, outside the submitted work; Stefan K. Barta reports personal fees from Acrotech, Affimed, Daiichi Sankyo, Janssen, Seagen, and Kyowa Kirin, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}